Drug Trial Radar · NCT07837115
A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food Effect on the Pharmacokinetics of Irafamdastat in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Oct 6, 2026
Primary completion
Dec 19, 2026
Study completion Dec 19, 2026
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Sep 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the relative bioavailability of irafamdastat and to assess food-effect on the pharmacokinetics (PK) of irafamdastat ODT in healthy adult participants.
Conditions
- Healthy Volunteers
Interventions
IrafamdastatDrug
Specified dose on specified days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Up to Day 19
- Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))Time frame: Up to Day 19
- Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))Time frame: Up to Day 19
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CenExel ACT (Formerly Anaheim Clinical Trials; LLC)
Anaheim, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.